Phosphorylated SNAP25 in the CA1 regulates morphine‐associated contextual memory retrieval via increasing GluN2B‐NMDAR surface localization

Wang, Xinjuan; Liu, Yan; Meng, Jia; Sun, Xiaowei; Wang, Na; Li, Yijing; Cui, Cai-Lian

doi:10.1111/adb.12558

Cited by 9 publications

(2 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Genes in the calcium channel signaling pathway are associated with OUD [16]. Studies have also linked SNAP-25 to antipsychotic treatment response [48], morphine-associated contextual memory retrieval [49], and the risk of attention deficit hyperactivity disorder [50]. The top variant rs592026 (Supplemental Figure S4D) in SNAP-25-AS1 is located 113 kb upstream of SNAP-25 and is an expression quantitative trait locus for SNAP-25 in thalamus (p = 1.8 × 10 −4 ).…”

Section: Discussionmentioning

confidence: 99%

Genome-Wide Association Study of Opioid Cessation

Cox

Sherva

Lunetta

et al. 2020

JCM

View full text Add to dashboard Cite

The United States is experiencing an epidemic of opioid use disorder (OUD) and overdose-related deaths. However, the genetic basis for the ability to discontinue opioid use has not been investigated. We performed a genome-wide association study (GWAS) of opioid cessation (defined as abstinence from illicit opioids for >1 year or <6 months before the interview date) in 1130 African American (AA) and 2919 European ancestry (EA) participants recruited for genetic studies of substance use disorders and who met lifetime Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for OUD. Association tests performed separately within each ethnic group were combined by meta-analysis with results obtained from the Comorbidity and Trauma Study. Although there were no genome-wide significant associations, we found suggestive associations with nine independent loci, including three which are biologically relevant: rs4740988 in PTPRD (pAA + EA = 2.24 × 10−6), rs36098404 in MYOM2 (pEA = 2.24 × 10−6), and rs592026 in SNAP25-AS1 (pEA = 6.53 × 10−6). Significant pathways identified in persons of European ancestry (EA) are related to vitamin D metabolism (p = 3.79 × 10−2) and fibroblast growth factor (FGF) signaling (p = 2.39 × 10−2). UK Biobank traits including smoking and drinking cessation and chronic back pain were significantly associated with opioid cessation using GWAS-derived polygenic risk scores. These results provide evidence for genetic influences on opioid cessation, suggest genetic overlap with other relevant traits, and may indicate potential novel therapeutic targets for OUD.

show abstract

Section: Discussionmentioning

confidence: 99%

Genome-Wide Association Study of Opioid Cessation

Cox

Sherva

Lunetta

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…The detailed procedure of CPP paradigm was performed as previously described with minor modifications. 24 The CPP apparatus contained three Plexiglas compartments connected through guillotine doors. The two larger compartments (17 Â 15 Â 28 cm 3 )…”

Section: Cpp Paradigmmentioning

confidence: 99%

2‐Fluorodeschloroketamine has similar abuse potential as ketamine

et al. 2022

Addiction Biology

View full text Add to dashboard Cite

2‐Fluorodeschloroketamine (2‐FDCK) as a substitute for ketamine has emerged among drug abusers in recent years. However, 2‐FDCK has not been controlled or regulated in many countries, which may be partly related to the lack of evidence on its abuse potential. In this study, we evaluated the abuse potential of 2‐FDCK via the tests of the conditioned place preference (CPP), locomotor sensitization, drug self‐administration and drug discrimination using ketamine as a reference. 2‐FDCK induced significant CPP at a minimum dose of 3 mg/kg in mice, an effect comparable with that of ketamine (3 mg/kg). Acute injections of 2‐FDCK or ketamine at 30 mg/kg enhanced locomotor activity. Repeated treatments with this dose of 2‐FDCK and ketamine induced locomotor sensitization after withdrawal. 2‐FDCK readily induced self‐administration with 0.5 mg/kg/infusion, the same dose for ketamine, and induced the highest seeking response at 1 mg/kg. Drug discrimination test showed that 2‐FDCK dose‐dependently substitute for ketamine with comparable ED50 to ketamine in substitution testing. Taken together, these results strongly suggested that 2‐FDCK has an abuse potential comparable with ketamine.

show abstract

Complement Factor H Displays Opposite Expression Patterns Under Two Situations of Methamphetamine Administration: Acute Exposure and Chronic Dependence

Lin

Liu

et al. 2020

Neurosci. Bull.

View full text Add to dashboard Cite

Phosphorylated SNAP25 in the CA1 regulates morphine‐associated contextual memory retrieval via increasing GluN2B‐NMDAR surface localization

Cited by 9 publications

References 48 publications

Genome-Wide Association Study of Opioid Cessation

Genome-Wide Association Study of Opioid Cessation

2‐Fluorodeschloroketamine has similar abuse potential as ketamine

Complement Factor H Displays Opposite Expression Patterns Under Two Situations of Methamphetamine Administration: Acute Exposure and Chronic Dependence

Contact Info

Product

Resources

About